Voriconazole activity against clinical yeast isolates: A multicentre Italian study

International Journal of Antimicrobial Agents

Volumn 26, Issue 3, 2005, Pages 247-253

  Morace, Giulia ^a   Polonelli, Luciano ^b  

^a UNIVERSITY OF MILAN   (Italy)

^b UNIVERSITY OF PARMA   (Italy)

Author keywords

Comparative methods; Voriconazole; Yeast susceptibility testing

Indexed keywords

FLUCONAZOLE; PYRROLE DERIVATIVE; VORICONAZOLE;

ANALYTIC METHOD; ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL ACTIVITY; ARTICLE; CANDIDA; CANDIDA ALBICANS; CANDIDA DUBLINIENSIS; CANDIDA FAMATA; CANDIDA GLABRATA; CANDIDA GUILLIERMONDII; CANDIDA INCOSPICUA; CANDIDA KEFYR; CANDIDA KRUSEI; CANDIDA LUSITANIAE; CANDIDA PARAPSILOSIS; CANDIDA PELLICULOSA; CANDIDA SAKE; CANDIDA TROPICALIS; CONTROLLED STUDY; CRYPTOCOCCUS NEOFORMANS; DIFFUSION; DILUTION; FUNGUS ISOLATION; GEOTRICHUM CAPITATUM; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; SACCHAROMYCES CEREVISIAE; TRICHOSPORON ASAHII; YEAST;

ANTIFUNGAL AGENTS; CANDIDA; CRYPTOCOCCUS NEOFORMANS; DRUG RESISTANCE, FUNGAL; FUNGI; GEOTRICHUM; HUMANS; INPATIENTS; ITALY; MICROBIAL SENSITIVITY TESTS; MYCOSES; OUTPATIENTS; PYRIMIDINES; SACCHAROMYCES CEREVISIAE; TRIAZOLES; TRICHOSPORON;

EID: 24044520969     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2005.06.005     Document Type: Article

References (25)

1. M.M. McNeil, S.L. Nash, and R.A. Hajjeh Trends in mortality due to invasive mycotic diseases in the United States, 1980-1997 Clin Infect Dis 33 2001 641 647
2. W. Hope, A. Morton, and D.P. Eisen Increase in prevalence of nosocomial non-Candida albicans candidaemia and the association of Candida krusei with fluconazole use J Hosp Infect 50 2002 56 65
3. S. Takakura, N. Fujihara, and T. Saito National surveillance of species distribution in blood isolates of Candida species in Japan and their susceptibility to six antifungal agents including voriconazole and micafungin J Antimicrob Chemother 53 2004 283 289
4. M.A. Pfaller, S.A. Messer, and L. Boyken Geographic variation in the susceptibilities of invasive isolates of Candida glabrata to seven systemically active antifungal agents: a global assessment from the ARTEMIS antifungal surveillance program conducted in 2001 and 2002 J Clin Microbiol 42 2004 3142 3146
5. H. Wisplinghoff, T. Bischoff, and S.M. Tallent Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study Clin Infect Dis 39 2004 309 317
6. Pfaller MA, Diekema DJ, Jones RN, Messer SA, Hollis RJ; SENTRY Participants Group. Trends in antifungal susceptibility of Candida spp. isolated from pediatric and adult patients with bloodstream infections: SENTRY antimicrobial surveillance program, 1997 to 2000. J Clin Microbiol 2002;40:852-6.
7. M.A. Pfaller, S.A. Messer, R.J. Hollis, R.N. Jones, and D.J. Diekema In vitro activities of ravuconazole and voriconazole compared with those of four approved systemic antifungal agents against 6,970 clinical isolates of Candida spp Antimicrobial Agents Chemother 46 2002 1723 1727
8. Tortorano AM, Rigoni AL, Biraghi E, Prigitano A, Viviani MA; The FIMUA-ECMM Candidaemia Study Group. The European Confederation of Medical Mycology (ECMM) survey of candidaemia in Italy: antifungal susceptibility patterns of 261 non-albicans Candida isolates from blood. J Antimicrob Chemother 2003;53:679-82.
9. Y.F. Berrouane, L.A. Herwaldt, and M.A. Pfaller Trends in antifungal use and epidemiology of nosocomial yeast infections in a university hospital J Clin Microbiol 37 1999 531 537
10. D.J. Sheehan, C.A. Hitchcock, and C.M. Sibley Current and emerging azole antifungal agents Clin Microbiol Rev 12 1999 40 79
11. F.C. Odds, A.J.P. Brown, and N.A.R. Gow Antifungal agents: mechanism of action Trends Microbiol 11 2003 272 279
12. D.W. Denning Echinocandin antifungal drugs Lancet 362 2003 1142 1151
13. P.G. Pappas, J.H. Rex, and J.D. Sobel Guidelines for treatment of candidiasis Clin Infect Dis 38 2004 161 189
14. K.A. Marr Empirical antifungal therapy - new options, new tradeoffs N Engl J Med 346 2002 278 280
15. National Committee for Clinical Laboratory Standards. Reference method for broth dilution antifungal susceptibility testing of yeasts. 2nd ed. Approved Standard, M27-A2. Villanova, PA: NCCLS; 2002.
16. N.G. Warren, and K.C. Hazen Candida, Cryptococcus, and other yeasts of medical importance P.R. Murray E.J. Baron M.A. Pfaller F.C. Tenover R.H. Yolkin Manual of clinical microbiology 7th ed. 1999 ASM Press Washington, DC 1184 1199
17. G. Morace, G. Amato, and F. Bistoni Multicenter comparative evaluation of six commercial systems and the National Committee for Clinical Laboratory Standards M27-A broth microdilution method for fluconazole susceptibility testing of Candida species J Clin Microbiol 40 2002 2953 2958
18. M.A. Pfaller, A. Barry, and J. Bille Quality control limits for voriconazole disk susceptibility tests on Mueller-Hinton agar with glucose and methylene blue J Clin Microbiol 42 2004 1716 1718
19. A.L. Barry, M.A. Pfaller, and S.D. Brown Quality control limits for broth microdilution susceptibility tests of ten antifungal agents J Clin Microbiol 38 2000 3457 3459
20. L. Ostrosky-Zeichner, J.H. Rex, and P.G. Pappas Antifungal susceptibility survey of 2,000 bloodstream Candida isolates in the United States Antimicrobial Agents Chemother 47 2003 3149 3154
21. K.C. Hazen, E.J. Baron, and A. Lopes Colombo Comparison of the susceptibility of Candida spp. to fluconazole and voriconazole in a 4-year global evaluation using disk diffusion J Clin Microbiol 41 2003 5623 5632
22. D. Swinne, M. Watelle, M. van der Flaes, and N. Nolard In vitro activities of voriconazole (UK-109, 496), fluconazole, itraconazole and amphotericin B against 132 non-albicans bloodstream yeast isolates (CANARI study) Mycoses 47 2004 177 183
23. F. Marco, C. Danés, and A. Almela Trends in frequency and in vitro susceptibilities to antifungal agents, including voriconazole and anidulafungin, of Candida bloodstream isolates. Results from a six-year study (1996-2001) Diagn Microbiol Infect Dis 46 2003 259 264
24. A. Favel, A. Michel-Nguyen, and A. Datry Susceptibility of clinical isolates of Candida lusitaniae to five systemic antifungal agents J Antimicrob Chemother 53 2004 526 529
25. M. Drago, M.M. Scaltrito, and G. Morace In vitro activity of voriconazole and other antifungal agents against clinical isolates of Candida glabrata and Candida krusei Eur J Clin Microbiol Infect Dis 23 2004 619 624